ClinicalTrials.gov
ClinicalTrials.gov Menu

Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management (CANDY-CANE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02608177
Recruitment Status : Recruiting
First Posted : November 18, 2015
Last Update Posted : October 6, 2017
Sponsor:
Collaborators:
American Diabetes Association
Medtronic
Abbott
Information provided by (Responsible Party):
Ian deBoer, University of Washington

Brief Summary:
The goal of this study is to test whether a dipeptidyl peptidase-4 inhibitor, compared with a sulfonylurea, improves time in normal blood glucose range and reduces blood glucose variability. Blood glucose is measured using a continuous glucose monitoring device.

Condition or disease Intervention/treatment Phase
Chronic Kidney Diseases Type 2 Diabetes Drug: Linagliptin Drug: Glipizide Not Applicable

Detailed Description:
This is a proof-of-concept clinical trial testing the effects of linagliptin versus glipizide on glucose variability among people with type 2 diabetes and stage 3-4 CKD. In a cross-over design, each enrolled participant will receive 28 days of each study medication. Study medications will be provided in a randomly assigned order without blinding. The primary study outcome is glucose time in range, measured by blinded continuous glucose monitoring for the last 6 days of each 28-day treatment period. Secondary outcomes include indices of glycemic variability, hypoglycemia, and biomarkers of systemic inflammation, oxidative stress, and albuminuria. The overall goal of this research is to identify safe and effective treatments to control glycemia among patients with diabetes and CKD.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
Study Start Date : November 2015
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Linagliptin/Glipizide
Arm receives 4 weeks of study drug linagliptin followed by 4 weeks of glipizide
Drug: Linagliptin
Receives 4 weeks of study drug linagliptin

Drug: Glipizide
Receives 4 weeks of study drug glipizide

Experimental: Glipizide/Linagliptin
Arm receives 4 weeks of study drug glipizide followed by 4 weeks linagliptin
Drug: Linagliptin
Receives 4 weeks of study drug linagliptin

Drug: Glipizide
Receives 4 weeks of study drug glipizide




Primary Outcome Measures :
  1. Glucose time in range [ Time Frame: 28 days ]

Secondary Outcome Measures :
  1. Glycemic variability [ Time Frame: 28 days ]
  2. Hypoglycemia [ Time Frame: 28 days ]
  3. Biomarkers of systemic inflammation [ Time Frame: 28 days ]
    Measured by plasma C-reactive protein (CRP)

  4. Biomarkers of systemic inflammation [ Time Frame: 28 days ]
    Measured by plasma interleukin-6

  5. Biomarkers of oxidative stress [ Time Frame: 28 days ]
    Measured by plasma F2-isoprostanes

  6. Biomarkers of oxidative stress [ Time Frame: 28 days ]
    Measured by urine F2-isoprostanes

  7. Biomarkers of albuminuria [ Time Frame: 28 days ]
    Measured by albumin-creatinine ratio



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 diabetes
  • eGFR 15-59 mL/min/1.73 m2
  • Hemoglobin A1c < 8%
  • Age ≥ 18 years
  • Current use of sulfonylurea

Exclusion Criteria:

  • BMI > 40 kg/m2
  • Actively using CGM for clinical care
  • End stage renal disease needing dialysis
  • Kidney transplant
  • Pregnant or nursing
  • Unable to provide informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02608177


Contacts
Contact: Laura Curtin (206) 221-3938 lcurtin@uw.edu
Contact: Connor Henry chenry@uw.edu

Locations
United States, Washington
University of Washington Recruiting
Seattle, Washington, United States
Contact: Laura Curtin    206-221-3938      
Sponsors and Collaborators
University of Washington
American Diabetes Association
Medtronic
Abbott
Investigators
Principal Investigator: Ian de Boer, MD University of Washington

Responsible Party: Ian deBoer, Associate Professor, Medicine/Nephrology, University of Washington
ClinicalTrials.gov Identifier: NCT02608177     History of Changes
Other Study ID Numbers: 50084-A
First Posted: November 18, 2015    Key Record Dates
Last Update Posted: October 6, 2017
Last Verified: October 2017

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency
Linagliptin
Glipizide
Hypoglycemic Agents
Physiological Effects of Drugs
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action